Innovative Medicine Initiative Discussions in Copenhagen
University of Copenhagen
Benzon Auditorium, Building 12
2100 København Ø
The IMI Science Team & University of Copenhagen
EFPIA Science visit Copenhagen
The European Federation of Pharmaceutical Industries and Associations (EFPIA) has since 2007 acted as the private partner in the European Public Private partnership Innovative Medicine Initiative (IMI) focusing on open innovation processes and drug development in Europe. IMI1 was part of the 7th Framework Programme whereas IMI2 is part of Horizon 2020. IMI2 is expected to launch their next call in June 2019 with an expected EU contribution of app. 200 MEUR and a matching amount from industry.
On the occasion of the EFPIA science team visit to Denmark University of Copenhagen is organising an open information meeting about the forthcoming IMI call. The meeting will provide insights on the IMI concept and paradigm, type of research projects and particular specificities of the programme. Additionally, the meeting will present the background industrial and political priorities and content of the call to be realesed in June 2019. The meeting is open for scientific, technical and administrative staff at all universities and hospitals in Denmark, private companies and other stakeholders in health and medical research.
Public-private partnership on health innovation in Europe
In 2021 the European Commission will launch the European research programme Horizon Europe with a budget of around €7-8 bn. for health and medical research. Part of the programme is likely to be implemented through a health innovation public-private partnership (PPP) with pharmaceutical and health & medical technology industries. This partnership will build on the Innovative Medicines Initiative (IMI) in which EFPIA (industry association for pharmaceutical companies) is the primary private partner. Denmark has a strong research and innovation ecosystem with state of art academic, clinical and applied research in medicine, drug development and technologies, world leading industries and innovative small and medium sized companies. Therefore, Danish stakeholders are well positioned to contribute to the implementation of the future PPP in health innovation.
Roundtable workshop on industry-led health innovation
The University of Copenhagen proposes to organise a scientific roundtable workshop focusing on opportunities related to the future European PPP vehicle for health innovation in Europe. The aims of the roundtable workshop are to:
- Raise awareness among key Danish stakeholders on the perspectives of the future health innovation PPP.
- Discuss opportunities and challenges in a cross-sector/cross-disciplinary industry-led research programme.
- Recommend concrete ideas for research fields/areas that are relevant to include in the strategic research & innovation agenda of the PPP.
The workshop will gather selected experts from the European pharmaceutical industry, potentially health technology industrial stakeholders, academia and clinical research in Denmark (in particular from universities in the Copenhagen area). Additionally, policy makers in research, innovation and health regulation are invited. The workshop programme/agenda will consist of a brief introduction to IMI2 and its impact and the initial thoughts about the future health innovation PPP, three break out sessions on specific thematic areas and plenary wrap up.
12:00-12:30 Registration, light lunch, networking
12:30-12:40 Welcome and brief introduction. Trine Winterø, Vice-dean for Innovation & External Relations, University of Copenhagen, Faculty og Health & Medical Sciences.
12:40-13:20 IMI2 & call 18 June 2019. Magda Chlebus, Executive Director for Science Policy & Regulatory Affairs, EFPIA
13:20-13:30 IMI from a national perspective. Kim Kryger, Senior Adviser, National Contact Point, Horizon 2020 Health & IMI2, Ministry for Education & Research
13:30-13:45 Q&A. TBC University of Copenhagen, Faculty og Health & Medical Sciences.
13:45-13:50 Wrap up. TBC University of Copenhagen, Faculty og Health & Medical Sciences.
To sign up for the EFPIA event (12:00-13:50) please register here (Registration Deadline: 21 May 2019 9:00)
Workshop agenda 14:00-17:00
14:00-14:10 Welcome and introduction
14:10-14:30 European PPP on health innovation 2021-2027. Magda Chlebus, Executive Director for Science Policy & Regulatory Affairs, EFPIA
14:30-15:30 Break out in thematic sessions: Regulatory Aspects; Patient Perspectives; Healthy Animal Production
15:40-16:00 Wrap up from thematic sessions. Thematic session moderators
16:00-16:15 Comments and perspectives. Magda Chlebus, Executive Director for Science Policy & Regulatory Affairs, EFPIA
16:15-17:00 Informal drink & networking
To sign up for the workshop (14:00-17:00) please register here here (Registration Deadline: 21 May 2019 9:00)
Workshop thematic sessions
In addition to playing a critical role in treatment of the individual, the development of new health technologies and system therapeutics are important in shaping our future health care systems and the interaction between health care professionals and individual citizens. Further, as health care technologies represent a significant part of the societal economy in terms of purchasing and in resources devoted to development, production and distribution, the collective impact of these emerging health technologies and new pharmaceutics will be of enormous scale. The question is: how can we assess and regulate this development to achieve the highest level of efficiency and safety at the societal level - and for the individual citizens? To take on that challenge, there is an increased need for further advancing cross-sectorial and technological integration. A workshop on regulatory aspects will have an outset in the future general opportunities/challenges relating to Innovative products and interventions and Digitisation. The workshop will address these topics with a view to highlight cross-sectorial and technological future possibilities within the following areas: De-risking innovation, product/services innovation and learning health systems.
Patient perspectives Many of IMI's activities are aimed at initiatives and new techniques that can streamline and upgrade clinical trials. In this field, the industry needs to be able to draw on both clinical and basic scientific expertise. So far, there have been mainly clinical trials of new drugs, but this is expected to be extended to include tests on new medical technology and health technology solutions. One example is telemedicine solutions in the field of pathology combined with artificial intelligence. For example, there is a wish to establish both a faster and more precise assessment of inclusion of patients in clinical trials based on images of pathologic anatomical tissue sections. The idea is that such images can be sent to a central site, where it can be determined by means of automated and fast image analysis whether a given patient can be included or not.
Healthy animal production with decreased use of antibiotics How do we increase animal health and decrease the use of antibiotics in animal production in order to combat antimicrobial resistance in both animals and humans? The focus could be on animal gut health and nutrition e.g. prevention of diarrhea and reduction of antibiotic consumption via dietary interventions, but also other types of interventions to reduce AMR could be relevant.